FLT3 Receptors with Internal Tandem Duplications Promote Cell Viability and Proliferation by Signaling Through Foxo Proteins
Overview
Affiliations
In about 30% of the patients with acute myeloid leukemia, activating FLT3 receptor mutations have been identified, often as in-frame internal tandem duplications (ITD) at the juxtamembrane domain of the receptor. FLT3-ITD receptors exhibit constitutive tyrosine kinase activity in the absence of FLT3 ligand (FL) binding, and when expressed in cytokine-dependent cell lines and primary hematopoietic cells suppress programmed cell death and increase cell division. However, the signaling pathways important for transformation, in particular the nuclear targets, are unknown. Here we demonstrate that FLT3-ITD expression in Ba/F3 cells results in activation of Akt and concomitant phosphorylation of the Forkhead family member Foxo3a. Phosphorylation of Foxo proteins through FLT3-ITD signaling promotes their translocation from the nucleus into the cytoplasm, which requires the presence of conserved Akt phosphorylation sites in Forkhead transcription factors and PI3K activity. Induction of Foxo3a phosphorylation by FLT3-ITD receptors in Ba/F3 cells correlates with the suppression of Foxo-target genes p27Kip1 and the proapoptotic Bcl-2 family member Bim. Specifically, FLT3-ITD expression prevents Foxo3a-mediated apoptosis and upregulation of p27Kip1 and Bim gene expression. These data indicate that the oncogenic tyrosine kinase FLT3 can negatively regulate Foxo transcription factors, thereby promoting cell survival and proliferation.
Chakravarti N, Boles A, Burzinski R, Sindaco P, Isabelle C, McConnell K Sci Rep. 2024; 14(1):9305.
PMID: 38653804 PMC: 11039474. DOI: 10.1038/s41598-024-59994-5.
Using published pathway figures in enrichment analysis and machine learning.
Shin M, Pico A BMC Genomics. 2023; 24(1):713.
PMID: 38007419 PMC: 10676589. DOI: 10.1186/s12864-023-09816-1.
Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia.
Sharma P, Borthakur G Cancer Drug Resist. 2023; 6(3):567-589.
PMID: 37842232 PMC: 10571063. DOI: 10.20517/cdr.2023.12.
Rahmati A, Mafi A, Soleymani F, Babaei Aghdam Z, Masihipour N, Ghezelbash B Front Oncol. 2023; 13:1149187.
PMID: 37124518 PMC: 10140500. DOI: 10.3389/fonc.2023.1149187.
Qiu Y, Li Y, Chai M, Hua H, Wang R, Waxman S Cell Death Discov. 2023; 9(1):44.
PMID: 36739272 PMC: 9899255. DOI: 10.1038/s41420-023-01317-0.